DaVita (DVA) Tops Q3 EPS by 36c; Guides EPS Higher
DaVita (NYSE: DVA) reported Q3 EPS of $1.80, $0.36 better than the analyst estimate of $1.44. Revenue for the quarter came in at $2.92 billion versus the consensus estimate of $2.94 billion.
"I am proud of the hard work and dedication of our 65,000 teammates in delivering essential, life-preserving care to our patients," said Javier Rodriguez, CEO of DaVita Inc. "Due to their efforts, we have been able to sustain continuity of care despite the disruption caused by the pandemic, while maintaining our strategic focus on leading the transformation of kidney care."
DaVita sees FY2020 EPS of $7.35-$7.60, versus prior of $6.25-$6.75 and the consensus of $6.85. DaVita sees FY2020 revenue of $11.5-11.6 billion, versus prior of $11.5-$11.7 billion and the consensus of $11.6 billion.
For earnings history and earnings-related data on DaVita (DVA) click here.